AbbVie Close to $8 Billion Deal for Cerevel Therapeutics, Sources Say, Reuters Reports
--AbbVie is close to a deal to acquire Cerevel Therapeutics Holdings for about $8 billion, Reuters reports, citing people familiar with the matter.
--AbbVie is in talks to pay around $45 a share for Cerevel, which develops drugs for neurological conditions.
--AbbVie and Cerevel didn't immediately respond to requests for comment from Reuters.
Full article at https://www.reuters.com/markets/deals/abbvie-nears-roughly-8-billion-drug-developer-cerevel-sources-2023-12-06/
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 06, 2023 16:44 ET (21:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?